UNSPSC 51121910: Lanatoside c

This classification denotes a lanatoside, digilanide, and cardiac glycoside with the molecular formula C49H76O20, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5RR3JFZ771, chemically known as 3-((o beta-d-glucopyranosyl-(1-4)-o-3beta-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-12beta,14-dihydroxy-5beta-card-20(22)-enolide but generally known as lanatoside c, which bears US NIH Compound Identifier 3879.

UNSPSC 51121910 Lanatoside c, a Commodity code, captures the procurement of cardiac glycoside medications and related advanced life support pharmaceuticals by state and local health and emergency services agencies. State and local governments buy lanatoside c and related cardiac medications primarily for emergency medical services (EMS) and fire rescue operations, often bundled with other advanced life support agents such as epinephrine, adenosine, diltiazem, and labetalol. Issuing bodies include municipal fire rescue departments, state health and human services agencies overseeing pharmacy benefit programs, and cooperative purchasing alliances coordinating multi-state pharmaceutical procurement on behalf of government health facilities. The City of Tampa's Purchasing Department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the range of entities soliciting under or related to this code—from single-jurisdiction emergency services procurement to state-level pharmaceutical benefit management and regional cooperative purchasing vehicles.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department posted IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, with a bid due date of April 8, 2026, seeking 1,810 units of epinephrine and three other cardiac agents for Tampa Fire Rescue with an estimated contract value of $40,000.00 and a Small Local Business Enterprise (SLBE) sheltered market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at improving prescription fulfillment efficiency outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendors to maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards, with a contract term of two years and optional extensions through June 30, 2028.